|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-1-9
|
|
pubmed:abstractText |
Infliximab is used for treatment of Crohn's disease and, following the Active Ulcerative Colitis Trials (ACT) 1 and 2, it has been used as rescue and maintenance therapy in moderate and severe ulcerative colitis (UC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1365-2036
|
|
pubmed:author |
pubmed-author:ArebiNN,
pubmed-author:BansiDD,
pubmed-author:CampbellSS,
pubmed-author:CarpaniMM,
pubmed-author:GhoshSS,
pubmed-author:HaraRR,
pubmed-author:HarrisA WAW,
pubmed-author:LindsayJJ,
pubmed-author:MilestoneAA,
pubmed-author:RussoE AEA,
pubmed-author:ThillainayagamAA,
pubmed-author:TsaiH HHH,
pubmed-author:WaltersJJ,
pubmed-author:WestabyDD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
308-14
|
|
pubmed:meshHeading |
pubmed-meshheading:19035973-Adolescent,
pubmed-meshheading:19035973-Adult,
pubmed-meshheading:19035973-Aged,
pubmed-meshheading:19035973-Antibodies, Monoclonal,
pubmed-meshheading:19035973-Colectomy,
pubmed-meshheading:19035973-Colitis, Ulcerative,
pubmed-meshheading:19035973-Female,
pubmed-meshheading:19035973-Gastrointestinal Agents,
pubmed-meshheading:19035973-Humans,
pubmed-meshheading:19035973-Male,
pubmed-meshheading:19035973-Middle Aged,
pubmed-meshheading:19035973-Physician's Practice Patterns,
pubmed-meshheading:19035973-Remission Induction,
pubmed-meshheading:19035973-Retrospective Studies,
pubmed-meshheading:19035973-Treatment Outcome,
pubmed-meshheading:19035973-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England.
|
|
pubmed:affiliation |
Imperial College Healthcare NHS Trust, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
